ストックスクリーナーアプリを入手
0.6629
3.81%
0.0243
アフターアワーズ：
.67
0.0071
+1.07%
前日終値:
$0.6386
開ける：
$0.64
24時間の取引高:
755.23K
Relative Volume:
0.64
時価総額：
$125.55M
収益：
-
当期純損益:
$-274.18M
株価収益率:
-0.2615
EPS:
-2.5346
ネットキャッシュフロー:
$-198.33M
1週間 パフォーマンス:
-14.60%
1か月 パフォーマンス:
-12.28%
6か月 パフォーマンス:
-95.10%
1年 パフォーマンス:
-93.21%
1日の値動き範囲:
$0.64
$0.6877
1週間の範囲:
$0.63
$0.7792
52週間の値動き範囲:
$0.6211
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
名前
Neumora Therapeutics Inc
セクター
電話
(857) 760-0900
住所
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6629 | 125.55M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-03-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-07 | ダウングレード | Stifel | Buy → Hold |
| 2025-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-10-10 | 開始されました | BofA Securities | Buy |
| 2023-10-10 | 開始されました | Guggenheim | Buy |
| 2023-10-10 | 開始されました | JP Morgan | Overweight |
| 2023-10-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-10 | 開始されました | Stifel | Buy |
| 2023-10-10 | 開始されました | William Blair | Outperform |
すべてを表示
Neumora Therapeutics Inc (NMRA) 最新ニュース
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Should investors be concerned about Neumora Therapeutics Inc (NMRA)? - uspostnews.com
NMRA stock rated an Underperform by BofA Securities - knoxdaily.com
Wainwright maintains $18 target on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora Therapeutics (NASDAQ:NMRA) versus Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Comparison - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Barchart.com
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Capital International Investors - MarketBeat
It is Poised to be a Bull Market for Neumora Therapeutics Inc (NMRA) - Sete News
NMRA Stock Sees Surge of Approximately 8.37% in Last Five Days - knoxdaily.com
NMRA’s valuation metrics: A comprehensive analysis - uspostnews.com
Former Neumora CEO to lead Galapagos spinout - BioPharma Dive
Franklin Resources Inc. Sells 44,345 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat
Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Needham & Company LLC - MarketBeat
Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025 - openPR.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class ActionNMRA - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - PR Newswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. - Bluefield Daily Telegraph
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView
NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Neumora Therapeutics Inc (NMRA) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):